ライフサイエンスコーパス: long-term use

1 nulocytosis side effects associated with its long term use.

2 cal effects and biokinetic distribution with long-term use.

3 well short-duration usage measures predicted long-term use.

4 onal biocompatibility of the formulation for long-term use.

5 , most present significant side effects over long-term use.

6 es h(-1)), and relatively good stability for long-term use.

7 th limited potential side effects, even with long-term use.

8 are potential complications associated with long-term use.

9 positive airway pressure (CPAP) may predict long-term use.

10 developed which would be more applicable for long-term use.

11 t hospital discharge, but few have evaluated long-term use.

12 determine whether this effect persists with long-term use.

13 the significant risks associated with their long-term use.

14 tential harms of HRT, particularly regarding long-term use.

15 reast or endometrium) precludes recommending long-term use.

16 d hormones are effective, side-effects limit long-term use.

17 resulting in decreased bone formation during long-term use.

18 e, which prevents loss in sensitivity during long-term use.

19 mposite material also make it preferable for long-term use.

20 d as a means to improve biocompatibility for long-term use.

21 tent and high dose opioids may contribute to long-term use.

22 , most present significant side effects with long-term use.

23 er the medication was intended for short- or long-term use.

24 son's disease often produce dyskinesias with long-term use.

25 effects, well-tolerated, and appropriate for long-term use.

26 with methylphenidate remains effective after long-term use.

27 adverse effects, contributing to problematic long-term use.

28 lving cilostazol is safe and appropriate for long-term use.

29 re especially troubling in children and with long-term use.

30 adverse events or the risks associated with long-term use.

31 i-inflammatory drugs are not recommended for long-term use.

32 OP were maintained in most patients over the long term using a modified bleb needling technique, desp

33 ions were classified as recently acquired or long-term using a recent infection testing algorithm and

34 cific patterns of inpatient use and risk for long-term use after discharge.

35 Here, we derive long-term (using analytical calculations) and short-term

36 e musculoskeletal injuries and may result in long-term use and consequent harms.

37 there was no consistent association between long-term use and NHL for all NSAIDs combined, aspirin,

38 Data characterising the long-term use and safety of emtricitabine plus tenofovir

39 Ten percent reported long-term use, and 22% reported frequent use.

40 tion; however, emerging problems limit their long-term use, and an increasing number of patients inte

41 n skin model, indicated that MB was safe for long-term use, and did not cause irritation even at high

42 ral years is safe and effective, but data on long-term use are limited.

43 ramine was approved in the United States for long-term use as an appetite suppressant until it was re

44 rs are promising anticancer agents but their long-term use at high doses is associated with adverse c

45 ioid use, and (iv) quantify the variation of long-term use attributed to region, practice, and prescr

46 y the most apoptosis-resistant cells survive long-term using autophagy-derived nutrients when growth

47 irculatory support systems for short-term or long-term use: bridging to transplant as well as for rec

48 postmenopausal women, is not acceptable for long-term use by many women.

49 g the rate of benzodiazepine use, especially long-term use by older adults, little information is ava

50 lly effective and promote HSV-1 latency, and long-term use can cause side effects.

51 ection rates in renal transplant recipients, long-term use can contribute to eventual nephrotoxicity,

52 treatment is initially highly effective, its long-term use can result in a serious worsening of sympt

53 5%) had a higher proportion of patients with long-term use compared to the population average.

54 here was a significantly increased risk with long-term use compared with never use (for >5 years, HR

55 t 1.17 times (95% CI, 1.10-1.25) the risk of long-term use compared with those receiving <=400 MME.

56 .99]), whereas the overall OR for cumulative long-term use (continuous or noncontinuous) was close to

57 atment of anxiety disorders but have limited long-term use due to adverse effects.

58 Current measurement devices are limited for long-term use due to the fragility of newborn skin and t

59 The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to t

60 The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to t

61 results from the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial, in which the use

62 For each drug class, we calculated long-term use for more than 1 or 7 years, and dose escal

63 bridge to cardiac transplantation, but their long-term use for the purpose of enhancing survival and

64 Antiobesity medications are intended for long-term use given the chronic nature of obesity.

65 Continuous long-term use (>/=5 years) of low-dose aspirin was assoc

66 uss the most recent literature regarding the long-term use (>/=52 weeks of follow-up) of antivascular

67 ited States Food and Drug Administration for long-term use in adolescents.

68 t use at least 16 years before diagnosis and long-term use in age-adjusted analyses but not in multiv

69 ods in xenogeneic hosts and are suitable for long-term use in an immunoexclusion device in a discorda

70 Its long-term use in children with renal dysfunction after O

71 ., postoperative) and cancer pain, but their long-term use in chronic pain has met increasing scrutin

72 t or heat-induced defects, thus limiting its long-term use in devices.

73 it may be possible to store donor cells for long-term use in high-risk hosts.

74 ity with PIs could substantially limit their long-term use in highly active ARV therapy.

75 exerts antiproliferative properties and its long-term use in HT as primary immunosuppression (IS) is

76 Despite long-term use in humans, little is known about the effec

77 remains one of the major obstacles for their long-term use in optoelectronic devices.

78 Temsirolimus is designed for long-term use in patients and therefore represents a pos

79 ilotinib is effective and well-tolerated for long-term use in patients with imatinib intolerance.

80 ble and thus considered to be unsuitable for long-term use in patients with obesity.

81 Three medications with approval for long-term use in the treatment of obesity are currently

82 toxicity of CS2 has been documented from its long-term use in the viscose rayon industry.

83 ements, might be a cost-effective method for long-term use in these patients.

84 However, information about its long-term use in this population is limited.

85 ropic actions in human myocardium, but their long-term use increases mortality in patients with heart

86 opamine release and neuron activity, whereas long-term use is associated with blunting of the dopamin

87 calcium available for contraction, but their long-term use is associated with increased mortality due

88 immune diseases are limited in efficacy, and long-term use is associated with severe adverse events.

89 s may be used to attenuate chronic pain, but long-term use is complicated by the possible increase in

90 he potential for chronic nephrotoxicity, its long-term use is controversial.

91 a, the need to assess the potential risks of long-term use is essential.

92 an option if a woman does not breastfeed and long-term use is intended.

93 However their long-term use is limited because of the development of t

94 allergies or autoimmune diseases), but their long-term use is limited by severe side effects.

95 the primary cardiovascular endpoint, and its long-term use is not associated with an increased risk o

96 However, their long-term use is restricted by the occurrence of adverse

97 Despite the popularity of GCs in the clinic, long-term use leads to numerous side effects, driving th

98 in the treatment of chronic pain, but their long-term use leads to the development of physiological

99 With long-term use, levodopa causes motor complications inclu

100 ents acquire resistance to oxaliplatin after long-term use, limiting its therapeutic efficacy.

101 eless functionality, and are impractical for long-term use, making real-world implementation challeng

102 tential side effects of dexmedetomidine with long-term use needs further evaluation.

103 Epidemiological studies indicate that long term use of nonsteroidal anti-inflammatory drugs (N

104 develops as a complication of pacemaker use, long-term use of a central venous catheter (CVC), or can

105 In male physicians aged 65 years or older, long-term use of a daily multivitamin did not provide co

106 Long-term use of a tongue barbell increases the prevalen

107 Long-term use of ACE inhibitors may protect against canc

108 Long-term use of acyclovir for up to 10 years for HSV su

109 Because this is the first case of long-term use of AI vaccines in poultry, the Mexican lin

110 Long-term use of alternate-day, low-dose aspirin may red

111 that may have clinical implications for the long-term use of an L1-virus-like particle-based prophyl

112 These observations support the long-term use of anakinra for the treatment of patients

113 Long-term use of androgen deprivation in prostate cancer

114 cardiovascular morbidity and mortality with long-term use of angiotensin-converting enzyme inhibitor

115 of dexfenfluramine gave rise to widespread, long-term use of anorectics to treat obesity.

116 We report effective long-term use of anti-IL-2 therapy for an autoimmune ind

117 of chronic inflammatory diseases involves a long-term use of anti-inflammatory drugs such as cortico

118 bition accelerates disease, cautions against long-term use of anti-TNF-alpha therapeutics for AD, and

119 is is given to important questions regarding long-term use of anti-TNFalpha therapies.

120 Conclusions: Long-term use of antibiotics in late adulthood may be a

121 hese findings reinforce the need for prudent long-term use of antibiotics.

122 Until research fully substantiates that the long-term use of antioxidants is safe and effective, the

123 Long-term use of antioxidants such as vitamin C, lutein,

124 Long-term use of aspirin (>5 years: odds ratio = 0.76, 9

125 le clinical data do not support the routine, long-term use of aspirin dosages greater than 75 to 81 m

126 o assist clinicians with decisions regarding long-term use of asthma therapies, including omalizumab.

127 mune effector cells has implications for the long-term use of azathioprine in the management of infla

128 s that are lacking after SCI and restored by long-term use of baclofen.

129 The key factor in long-term use of batteries is the formation of an electr

130 r the current clinical guidelines advocating long-term use of beta-blockers to treat most forms of co

131 Recently published studies confirm that the long-term use of biological agents targeting TNF-alpha i

132 Recently published studies confirm that the long-term use of biologicals targeting tumor necrosis fa

133 t, we did not observe an association between long-term use of bisphosphonates and risk of colorectal

134 to be time-dependent with higher risk after long-term use of bisphosphonates in older MM patients of

135 tatus, smoking, cardiovascular risk factors, long-term use of bronchodilators or steroids for lung di

136 The long-term use of calcineurin inhibitors (CNIs) after liv

137 sts about breast cancer risk associated with long-term use of calcium channel blockers (CCBs) or angi

138 The long-term use of calcium channel blockers may be protect

139 tolerance and receptor down-regulation after long-term use of cannabinoids.

140 The long-term use of cannabis, particularly at high intake l

141 is known about the benefits and risks of the long-term use of cardiovascular drugs.

142 We examined the association between long-term use of cholesterol-lowering drugs, predominant

143 E-/- mice has important implications for the long-term use of cholinesterase inhibitors and other cho

144 Although effective, the long-term use of CNIs is associated with nephrotoxicity.

145 However, long-term use of CNIs is associated with some degree of

146 Long-term use of combination therapy against human immun

147 Long-term use of corticosteroids can lead to loss of bon

148 Long-term use of corticosteroids is associated with cons

149 Due to concerns regarding the safety of long-term use of COX-2 inhibitors as well as a desire to

150 S and biopsy-proven IgM nephropathy, and (2) long-term use of CsA in moderate doses with closely moni

151 Thus, long-term use of cultures to define homeostasis and woun

152 Long-term use of cyclosporine also is associated with a

153 Long-term use of decongestant nasal spray (alpha adrener

154 ping DES as a result of the inevitability of long-term use of digital devices among many categories o

155 Long-term use of dulaglutide was associated with reduced

156 onstrate any health concerns associated with long-term use of EC in relatively young users who did no

157 EXTEND demonstrated that long-term use of eltrombopag was effective in maintainin

158 Long-term use of epoprostenol further lowered PVR (-47%

159 Long-term use of G-CSF appears well tolerated and effect

160 High doses and long-term use of glucocorticoids lead to an important an

161 Despite long-term use of high doses of atracurium infusion and t

162 nts might develop substantial morbidity from long-term use of high doses of these drugs.

163 e healing in our mouse model is dependent on long-term use of high-dose bisphosphonates, immunosuppre

164 to the growing body of evidence that recent long-term use of HRT is associated with an increased ris

165 and outer retinal involvement in short- and long-term use of hydroxychloroquine before the developme

166 Importance: Retinopathy is a known risk of long-term use of hydroxychloroquine sulfate.

167 The estimated risk reduction for long-term use of ibuprofen (RR, 0.51; CI, 0.28-0.96) was

168 To permit the long-term use of IFN, we propose combining low doses of

169 Long-term use of immunosuppressants is associated with s

170 d because of the hazards associated with the long-term use of immunosuppressive drugs.

171 minate much of the morbidity associated with long-term use of immunosuppressive medication.

172 Long-term use of individual beta-carotene, retinol, and

173 The data indicate caution in the long-term use of inhibition of host cell protein synthes

174 Conclusion Long-term use of insulin glargine is associated with an

175 Long-term use of ISDN/HYD therapy should be associated w

176 nalysis highlights potential consequences of long-term use of JNK inhibitors for the treatment of met

177 ad already developed side effects from their long-term use of L-dopa revealed, in some cases, the pre

178 of antiviral resistance have been found with long-term use of lamivudine, in up to 76% of patients tr

179 Long-term use of lead azide and lead styphnate as primar

180 If long-term use of left ventricular assist devices (LVADs)

181 Long-term use of levodopa is commonly associated with mo

182 We estimated the association between long-term use of lithium (>/=5 years) and risk of upper

183 idemiologic study of the association between long-term use of lithium and risk of upper urinary tract

184 Long-term use of lithium was observed among 0.22% of cas

185 r upper urinary tract cancer associated with long-term use of lithium.

186 a potential mechanistic explanation for why long-term use of low doses of NSAIDs, including aspirin,

187 (VTE) in high-risk patients, but whether the long-term use of low-dose aspirin reduces risk in health

188 y, the trial findings do not support routine long-term use of low-dose clarithromycin.

189 Long-term use of low-dose combination OCs did not increa

190 arding disease prognosis and decisions about long-term use of medical, endoscopic, and diet therapies

191 e associated with postoperative symptoms and long-term use of medication.

192 The benefits of long-term use of methylphenidate treatment in children a

193 tes of antidepressant use and a reduction in long-term use of minor tranquilizers for up to 2 years,

194 d emphasizes the avoidance of indiscriminate long-term use of molecular targeted drugs.

195 tanding the molecular changes in response to long-term use of morphine is likely to aid in the develo

196 Long-term use of morphine leads to development of antino

197 Long-term use of MTX for JRA does not appear to be assoc

198 Long-term use of multivitamins may substantially reduce

199 Long-term use of nicotine has been linked with self-medi

200 studies and clinical trials demonstrate that long-term use of non-steroidal anti-inflammatory drugs (

201 s of epidemiological studies have shown that long-term use of non-steroidal anti-inflammatory drugs,

202 term, continuous use of low-dose aspirin and long-term use of nonaspirin NSAIDs were associated with

203 ventive agents and difficulties in assessing long-term use of nonprescription medications.

204 Epidemiological studies have shown that long-term use of nonsteroidal anti-inflammatory drugs (N

205 dies suggest reduced AD risk associates with long-term use of nonsteroidal anti-inflammatory drugs (N

206 Epidemiological studies have shown that long-term use of nonsteroidal antiinflammatory drugs (NS

207 The association between long-term use of nonsteroidal antiinflammatory drugs (NS

208 uman epidemiological studies have identified long-term use of NSAIDs as protective against AD.

209 Epidemiologic studies demonstrate that long-term use of NSAIDs is associated with a reduced ris

210 t pattern in this research is that continued long-term use of NSAIDs is required for an anticancer ef

211 Long-term use of NSAIDs, especially ASA, is associated w

212 uct stability and efficacy is crucial to the long-term use of nucleic-acid based medicines.

213 a nationwide analysis of patients in Sweden, long-term use of OCs, particularly the combination type,

214 novel animal model to examine the effects of long-term use of omeprazole.

215 In light of the increasing long-term use of opiates in chronic pain, in principle,

216 (PT) interventions before or after TKR with long-term use of opioids are not known.

217 lopment of strategies that could improve the long-term use of opioids for pain.

218 SCD is mostly reliant upon opioids; however, long-term use of opioids is associated with multiple sid

219 Another evolving concern is whether the long-term use of opioids is safe and effective.

220 o functional status markers were improved by long-term use of opioids.

221 Little is known of the risks associated with long-term use of oral bisphosphonates despite their use

222 acquisition decreased with age, income, and long-term use of oral contraceptives and increased with

223 onsistent with the observation in women that long-term use of oral contraceptives or multiple pregnan

224 Long-term use of oral corticosteroids has known adverse

225 ncy department, the use of rescue therapy or long-term use of oral corticosteroids, or the dispensing

226 lls (PBMCs) from 17 adult asthmatics after a long-term use of oral glucocorticoid.

227 acture risk assessment for all patients with long-term use of oral glucocorticoids is required.

228 Widespread and long-term use of oral nucleos(t)ide analogs (NAs) to tre

229 egrity in most osteoporotic patients and the long-term use of osteoporosis drugs is controversial.

230 , strengthened research to better inform the long-term use of osteoporotic drug therapies is delineat

231 exacerbates pathogenesis and argues against long-term use of pan-anti-TNF-alpha inhibitors for the t

232 rt previous genetic analyses suggesting that long-term use of PCSK9 inhibitors, like statins, may be

233 ), high levels of physical activity, and the long-term use of pharmacotherapy combined with lifestyle

234 Relative to nondiabetics, the cumulative long-term use of pioglitazone reduced the dementia risk

235 Long-term use of pioglitazone was associated with a lowe

236 The long-term use of plasmapheresis may be a well-tolerated

237 op an animal model to examine the effects of long-term use of PPI in vivo.

238 f proton pump inhibitors (PPIs), focusing on long-term use of PPIs for three common indications: gast

239 We hypothesized that long-term use of PPIs is associated with greater microbi

240 In HIV, long-term use of PPIs was associated with increased micr

241 onal studies of outcomes associated with the long-term use of preventive therapies are subject to the

242 atter finding is potentially relevant to the long-term use of protein farnesyltransferase inhibitors,

243 observational studies, between high-dose or long-term use of proton pump inhibitor drugs and certain

244 Researchers have hypothesized that the long-term use of proton pump inhibitors (PPIs) can incre

245 iew is to evaluate the risks associated with long-term use of proton pump inhibitors (PPIs), focusing

246 s show that HIV infection, combined with the long-term use of psychostimulants, increases neuronal st

247 to accumulation of the (S)-enantiomer after long-term use of racemic albuterol.

248 No new safety events were identified with long-term use of ranibizumab; rates of SAEs potentially

249 These results support the long-term use of riociguat in patients with pulmonary ar

250 m outcome focusing on efficacy and safety of long-term use of rituximab maintenance.

251 ect of increasing brain serotonin signaling, long-term use of selective serotonin reuptake inhibitor

252 Current long-term use of SSRI (>/=20 prescriptions) was not asso

253 Long-term use of statins among patients with CAD appeare

254 These results suggest that long-term use of statins is unlikely to substantially in

255 PIMs included: long-term use of stimulant laxatives and high-dosages of

256 Then we evaluated the long-term use of subcutaneous ICDs in a pilot study, inv

257 The potential hazards associated with long-term use of such doses should be carefully consider

258 We examined the association between long-term use of supplemental B vitamins on the one-carb

259 The effect that long-term use of suppressive acyclovir (ACV) has on both

260 Long-term use of suppressive prophylactic ACV appears to

261 Long-term use of systemic antifungals is not optimal due

262 The long-term use of tamoxifen and other selective estrogen

263 Long-term use of the CSD lowered end-diastolic and end-s

264 Toxicities have been reported with long-term use of the other triazoles.

265 Recently, long-term use of these agents has come under scrutiny du

266 improves cytopenias in 50% of patients, but long-term use of these can lead to toxicity.

267 Unfortunately, the long-term use of these devices is compromised by cellula

268 Furthermore, long-term use of these devices is not associated with in

269 rm trials, the current evidence supports the long-term use of these drugs for the treatment of patien

270 onsteroidal analgesics and opiates; however, long-term use of these drugs is commonly associated with

271 y reduces inflammation, pain, and fever, and long-term use of these drugs reduces fatal thrombotic ev

272 ilar to those in patients on diclofenac with long-term use of these drugs.

273 rdive dystonia may become irreversible after long-term use of these drugs.

274 Studies over the past decade suggest that long-term use of these heparins in both primary and seco

275 ing fetal exposure to drugs and xenobiotics, long-term use of these medications may affect fetal drug

276 Unfortunately, the long-term use of these therapies is complicated by unwan

277 d with GSK2330672 treatment, might limit the long-term use of this drug.

278 Long-term use of topical corticosteroids in skin inflamm

279 and clinical studies have reported that the long-term use of topical medications in chronic ophthalm

280 ment of resistance is the main threat to the long-term use of toxins from Bacillus thuringiensis (Bt)

281 Long-term use of unopposed estrogen is associated with i

282 ator levels in patients with RA, despite the long-term use of various anti-inflammatory drugs, sugges

283 the highest adjusted odds ratios (aORs) for long-term use: older age (>=75 years, aOR 4.59, 95% CI 4

284 However, long-term use poses adherence challenges, is associated

285 and prostaglandin E2 (PGE2) expression, but long-term use produced significantly higher levels of th

286 however, the apparent benefit decreased with long-term use (relative risk, 0.80; 0.67 to 0.96, after

287 atients who began treatment in recent years, long-term use remains low.

288 other chronic conditions, but the safety of long-term use remains uncertain.

289 inflammatory drugs are widely prescribed but long-term use shows adverse effects that detract from pa

290 ubtedly cause irreversible brain damage with long-term use, the jury is still out on the party drug e

291 s early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effectiv

292 is glucocorticoids, their side effects make long-term use undesirable.

293 ations like opioids have drawbacks that make long-term use untenable.

294 ds, 8% had long-term opioid use, and risk of long-term use was 1.16 times [95% confidence interval (C

295 Obesity medications approved for long-term use, when prescribed with lifestyle interventi

296 cannabinoids has been widely observed after long-term use, with concomitant receptor desensitization

297 ageable safety and tolerability profile over long-term use, with no new safety signals.

298 tretchable, sensitive, and robust enough for long-term use without degradation in performance.

299 ile the PVP-based DMAP offered potential for long-term use without irritation.

300 ophageal reflux, which are now available for long-term use without medical supervision.